RxDoctor Payments Data

Paula Teixeira, PA

Medical · Raynham, MANPI 1720050768

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.

$2,096in general payments, 2019–2025

Across 95 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$451
  • AstraZeneca$263
  • Pfizer$238
  • Exact Sciences$155
  • GSK$131
  • Johnson & Johnson$120
  • plus $738 from 17 others

What the payments were for

  • Food & beverage$2,096100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,096 in reported general payments places this provider in the 85th percentile of 421 medical providers in Massachusetts.

See all medical providers in Massachusetts

Medicare billing

Part B allowed, 2024
$138,040
Medicare patients
223
Services billed
1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$15,711
Rosuvastatin Calcium239$13,136
Incruse ElliptaUmeclidinium Bromide27$10,107
XareltoRivaroxaban12$6,766
Atorvastatin Calcium429$5,089
Metoprolol Succinate247$4,338
Irbesartan76$3,415
Lisinopril245$2,212
Amlodipine Besylate321$2,129
Ezetimibe39$1,804
Mirtazapine61$1,316
Levothyroxine Sodium155$1,154
SynthroidLevothyroxine Sodium18$1,104
Escitalopram Oxalate70$1,037
Omeprazole84$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$238$15,71117 claims
GSKIncruse Ellipta$131$10,10727 claims
Johnson & JohnsonXarelto$120$6,76612 claims
AbbVieSynthroid$37$1,10418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 421 medical providers in Massachusetts.

Other medical in Raynham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →